shifting prognoses of patients with egfr-mutant nsclc
Published 6 years ago • 43 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
14:24
egfr-mutant lung cancer & treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
5:53
targeted therapy in non-small cell lung cancer
-
20:38
future research and treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
4:03
landscape of targeted therapies in lung cancer
-
4:44
understanding non-small cell lung cancer
-
5:02
egfr-mutant lung cancer: initial approach
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
37:44
deciphering the data in egfr - mutant nsclc
-
1:41
egfr mutations in patients with lung cancer
-
10:30
expert highlights: targeting her2 and egfr in nsclc | tejas patil
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:56
what targeted therapies are used for people with the egfr mutation?
-
3:55
egfr-mutant nsclc: optimizing therapy selection
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
2:02
understanding egfr resistance in patients with met-amplified nsclc